A study to look at the safety and effectiveness of baloxavir marboxil in treating children with influenza aged between 1 and <12 years (miniSTONE-2)

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

  • Infectious Diseases
  • Influenza
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Anaheim
  • Austin
  • Bardstown
  • Bellaire
  • Birmingham
  • Bridgeton
  • Bydgoszcz
  • Charleston
  • Charlotte
  • Cleveland
  • Dallas
  • Dayton
  • Dębica
  • Harrisburg
  • Houston
  • Idaho Falls
  • Jonesboro
  • Kingsport
  • Las Vegas
  • Los Angeles
  • Madrid
  • Monterrey
  • Omaha
  • Pensacola
  • Petah Tikva
  • Salt Lake City
  • Samara
  • San Diego
  • San José
  • Santiago de Compostela
  • Siemianowice Śląskie
  • Smithfield
  • Tomball
  • Topeka
  • Waxahachie
Trial Identifier:

NCT03629184 2018-002169-21 CP40563

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT03629184, CP40563, 2018-002169-21 Trial Identifier
      Baloxavir Marboxil, Oseltamivir Treatments
      Influenza Condition
      Official Title

      A Multicenter, Randomized, Double-Blind, Active (Oseltamivir)-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients 1 to <12 Years of Age With Influenza-Like Symptoms

      Eligibility Criteria

      All Gender
      ≥1 Year & ≤ 11 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Aged 1 to < 12 years at randomization (Day 1).
      • Written informed consent/assent for study participation obtained from participant's parents or legal guardian, with assent as appropriate by the participant, depending on the patient's level of understanding
      • Participant able to comply with study requirements, depending on the patient's level of understanding
      • Participant with a diagnosis of influenza virus infection confirmed by the presence of all of the following:
      • Fever ≥ 38 degree celsius (tympanic temperature) at screening
      • At least one respiratory symptom (either cough or nasal congestion)
      • The time interval between the onset of symptoms and screening is ≤ 48 hours
      Exclusion Criteria
      • Severe symptoms of influenza virus infection requiring inpatient treatment
      • Concurrent infections requiring systemic antiviral therapy at screening
      • Require, in the opinion of the investigator, any of the prohibited medication during the study
      • Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine within 2 weeks prior to screening
      • Immunization with a live/attenuated influenza vaccine in the 2 weeks prior to randomization
      • Concomitant treatment with steroids or other immuno-suppressant therapy
      • Known HIV infection or other immunosuppressive disorder
      • Uncontrolled renal, vascular, neurologic, or metabolic disease (e.g., diabetes, thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or participants with known chronic renal failure.
      • Active cancer at any site
      • History of organ transplantation
      • Known allergy to either study drug (i.e., baloxavir marboxil and oseltamivir) or to acetaminophen
      • Females with child-bearing potential
      • Participation in a clinical trial within 4 weeks or five half-lives of exposure to an investigational drug prior to screening, whichever is longer

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Influenza

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now